stockrowWhat it does
Spyre Therapeutics is a clinical-stage biotechnology company developing antibody medicines for inflammatory bowel disease (IBD) and rheumatic diseases. Founded on 2013-01-01, it is headquartered in Austin. It has not generated revenue from commercial product sales.
IBD includes ulcerative colitis and Crohn’s disease, conditions in which inflammation affects the digestive tract. Spyre is developing SPY001, SPY002 and SPY003 for IBD. Each is designed to act on a different target involved in inflammation: α4β7, TL1A or IL-23. The company is studying the antibodies individually and in pairs.
Spyre is also developing SPY072, an antibody targeting TL1A, for rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. These are inflammatory conditions that can affect joints, the spine or skin.
The candidates are engineered to remain in the body for longer. Spyre believes this could allow maintenance treatment by injection under the skin quarterly or twice annually. That dosing is a development goal, not an approved product schedule.
The company is running Phase 2 trials in patients with ulcerative colitis and in patients with the targeted rheumatic diseases. If a candidate is approved, Spyre intends to plan its commercialization in the United States and other key markets using its own infrastructure, external partnerships or both.
How it makes money
Spyre has not generated revenue from commercial product sales. Its future product revenue depends on developing its candidates, obtaining regulatory approval and bringing them to market. It has not yet established full commercial or distribution capabilities.
FY2025 reportable segment revenue was $0.00. A latest-quarter revenue total is not provided here.
The current portfolio centers on investigational antibodies rather than marketed medicines. SPY001, SPY002 and SPY003 are being tested individually for ulcerative colitis, as well as in the combinations SPY120, SPY130 and SPY230. SPY072 is being tested separately for rheumatic diseases. Spyre has not set out product prices in the available disclosures. Its intended maintenance injections could be repeated over time, but their dosing and commercial use remain subject to development and approval.
Spyre previously recognized license and development revenue associated with pegzilarginase, a legacy candidate whose global rights it sold to Immedica. During the twelve months ended December 31, 2025, Spyre recognized a gain of $10.0 million from reimbursement decision milestones under that sale. Milestone payments, net of allowable expenses and adjustments, are to be distributed to holders of contingent value rights under the associated agreement.
Operations have also been funded through stock and warrant issuances, grants and licensing proceeds. Spyre expects to need additional financing for research and development before a commercial drug can be produced, marketed and sold. It expects operating losses to increase as it continues clinical development and prepares for potential commercialization.
| Product or service | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| Development fee and royalty | $0.00 | — | — |
Customers and how it sells
Spyre’s intended patients include people with ulcerative colitis or Crohn’s disease and people with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis. Its SKYLINE trial is enrolling patients with moderately to severely active ulcerative colitis. Its SKYWAY trial studies SPY072 in patients with moderately to severely active forms of the three rheumatic diseases.
The company estimates that approximately 2.4 million individuals currently have IBD in the United States. It also describes existing treatment challenges, including inadequate or lost response and the inconvenience of frequent dosing.
Spyre intends to develop a commercialization plan for the United States and other key markets if any candidates are approved. That plan may use internal infrastructure, external partners or both. The company has not yet established full commercial or distribution capabilities, and it has not generated revenue from commercial product sales.
Outside the United States, Spyre would need the relevant national approvals before conducting clinical trials or marketing a product. Pricing and reimbursement requirements can also vary by country.
| Segment | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| Reportable Segment | $0.00 | — | — |
Suppliers and costs
Spyre does not own or operate facilities for product manufacturing, testing, storage or distribution. It outsources its nonclinical and clinical drug supply development and those activities to third parties. The company expects to enter longer-term commercial supply agreements as its programs advance.
WuXi Biologics provides development, manufacturing and testing services for the SPY001, SPY002 and SPY003 programs under work orders. Spyre also licenses WuXi Biologics cell-line technology used in manufacturing activities for those programs. Under specified circumstances, the license calls for royalties on sales of products made using that technology by another manufacturer.
Spyre is creating manufacturing capabilities with third parties outside China, including in the United States. It intends to establish domestic inventory of key materials and is accelerating clinical resupply campaigns.
Research and development has historically been the largest component of operating expenses. Costs include trial materials, payments to trial sites and contractors, research under the Paragon agreement, and employee and consultant compensation. Spyre expects expenses to increase as candidates move into larger trials and the company pursues approvals and potential commercialization.
- Revenue$886.0K
- Research and development−$89.5M
- Selling, general and administrative−$39.9M
- Other operating costs−$113.7M
- Operating income−$242.3M
Competitive position
If its IBD candidates are approved, Spyre expects them to compete with established treatments including AbbVie’s Humira and Skyrizi, Johnson & Johnson’s Stelara and Tremfya, and Takeda’s Entyvio. Biosimilars and generic medicines also compete or are in development. Other companies are developing IBD treatments, including Merck’s tulisokibart and Roche and Roivant’s afimkibart, which target TL1A.
For rheumatic diseases, SPY072 would face treatments from companies including AbbVie, Amgen, Johnson & Johnson, Roche and Lilly, as well as candidates in development. The competitive field differs by disease and includes antibodies and other types of medicines.
Spyre seeks patent protection for its programs, methods of use and related technologies. As of January 31, 2026, it exclusively licensed or owned four patent families directed to α4β7 antibodies, including SPY001. The company has exclusive licenses to intellectual property for SPY001 and SPY002 worldwide across therapeutic disorders; its SPY003 license is worldwide for IBD indications.
Our reading: Patent and license rights could protect elements of the portfolio, but their strength depends on maintaining and enforcing them. Our reading: Longer-lasting antibodies and combinations could differentiate Spyre’s candidates, but their clinical and commercial advantages remain unproven.
| Competitor | Where they compete | Threat (our reading) |
|---|---|---|
| AbbVie | IBD and rheumatic disease treatments | High |
| Johnson & Johnson | IBD and rheumatic disease treatments and candidates | High |
| Takeda | IBD antibody treatment | High |
| Merck | TL1A candidates for IBD and rheumatic diseases | High |
| Roche | Rheumatic disease treatments and TL1A candidate | High |
| Lilly | IBD and rheumatic disease treatments and candidates | High |
| Amgen | Rheumatic disease treatments | High |
| Roivant | TL1A candidate for IBD and rheumatoid arthritis | Medium |
Growth opportunities
Spyre’s growth plans depend on progressing its antibody candidates through clinical trials and, if successful, obtaining approvals and commercializing them. The company is pursuing individual treatments and combinations in IBD, alongside an expansion of its anti-TL1A program into rheumatic diseases.
In the SKYLINE Phase 2 trial, Spyre is evaluating SPY001, SPY002 and SPY003 in ulcerative colitis. Part A assesses each antibody individually. Part B is designed to assess monotherapies and combinations against placebo and provide dose-ranging and combination proof-of-concept data. Spyre expects Part A induction data to begin reading out in Q2 2026 and Part B induction data in 2027.
The SKYWAY Phase 2 trial evaluates SPY072 in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. Spyre expects topline proof-of-concept data for all three indications in Q4 2026.
The company’s product design aims to enable less frequent maintenance injections. It is also investigating whether combining antibodies that target different inflammatory pathways can improve efficacy compared with individual treatments. Those possibilities remain under study.
Spyre estimates that approximately 2.4 million individuals currently have IBD in the United States. It also estimates that rheumatoid arthritis affects more than 1.5 million individuals in the U.S. and that psoriatic arthritis affects approximately 0.8 million individuals in the U.S.
- $18.7MFY2021
- $2.3MFY2022
- $886.0KFY2023
Structural risks
- Funding: Spyre will need additional capital and says it will not be able to continue as a going concern if it cannot raise capital when needed. Financing may dilute shareholders, restrict operations or require the company to relinquish rights.
- Clinical development: Programs may fail, be delayed or cost more than anticipated. Trials may produce negative or inconclusive results, fail to demonstrate safety or efficacy, or require additional studies.
- Regulatory approval: Spyre may not meet its timelines or obtain timely approvals. Regulators may require further clinical, toxicology or manufacturing data before allowing trials to proceed or products to be marketed.
- Third parties and supply: The company relies on contractors and manufacturers for trials and supply. It is building capabilities outside China and monitoring geopolitical risks that could affect manufacturers.
- Competition and intellectual property: Spyre faces companies developing or selling treatments for the same diseases and mechanisms. It may also fail to obtain, maintain or protect patents and other proprietary rights.
Bottom line
Our reading
Spyre is a clinical-stage drug developer rather than a business with commercial product sales. Its potential rests on proving that its antibodies and combinations can treat inflammatory diseases and ultimately securing approval in competitive markets. It has resources for at least one year under its current operating plans, but future development and commercialization will require additional financing; manufacturing and clinical work also depend on outside parties.